Veru Inc. (VERU)
| Market Cap | 34.03M -55.7% |
| Revenue (ttm) | n/a |
| Net Income | -13.95M |
| EPS | -0.77 |
| Shares Out | 16.05M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 86,393 |
| Open | 2.150 |
| Previous Close | 2.110 |
| Day's Range | 2.063 - 2.239 |
| 52-Week Range | 2.050 - 7.400 |
| Beta | -1.17 |
| Analysts | Strong Buy |
| Price Target | 24.50 (+1,055.66%) |
| Earnings Date | May 13, 2026 |
About VERU
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly pat... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for VERU stock is "Strong Buy." The 12-month stock price target is $24.5, which is an increase of 1,055.66% from the latest price.
News
Veru price target lowered to $24 from $25 at Oppenheimer
Oppenheimer lowered the firm’s price target on Veru (VERU) to $24 from $25 to reflect the company’s Q2 results. The firm keeps an Outperform rating on the shares. Published first…
Veru Inc. Earnings Call Transcript: Q2 2026
Enobosarm showed strong phase II-B results in preserving lean mass and function in older obese patients on GLP-1 therapy, with a large market opportunity and ongoing phase II-B plateau study. Net loss narrowed and cash position improved, supporting continued R&D.
Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
--Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on track for i nterim analysis first quarter calendar year 2027 —
Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th
MIAMI, FL, May 06, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic an...
Veru files $200M mixed securities shelf
16:22 EDT Veru (VERU) files $200M mixed securities shelf
Veru files to sell 23.8M shares of common stock
16:16 EDT Veru (VERU) files to sell 23.8M shares of common stock
Veru enrolls first patient in Phase 2b PLATEAU trial of enobosarm
Veru (VERU) announced that it has enrolled the first patient in its Phase 2b PLATEAU clinical trial of enobosarm, an oral selective androgen receptor modulator, SARM, to preserve muscle and…
Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
-- The Phase 2b study to assess enobosarm's ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older patients...
Veru Inc. Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Enobosarm, combined with GLP-1, aims to address muscle loss and functional decline in older obese patients, with Phase 2b studies showing promising results in lean mass preservation and fat loss. The upcoming Plateau study targets regulatory approval through multiple endpoints, with top-line data expected in Q4 2027.
Veru Inc. Earnings Call Transcript: Q1 2026
Net loss narrowed to $5.3M as R&D and admin costs declined, with $33M in cash supporting operations through the next clinical milestone. Positive phase II-B results and FDA feedback advance enobosarm's development for obesity, targeting selective fat loss and muscle preservation.
Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th
MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a...
Veru initiated with a Buy at Canaccord
Canaccord initiated coverage of Veru (VERU) with a Buy rating and $25 price target Veru is positioned as a differentiated biotech in obesity drug development, with lead candidate enobosarm, an…
Veru Inc. Earnings Call Transcript: Q4 2025
Positive Phase 2b results for enobosarm showed preserved lean mass and enhanced fat loss in obese patients on GLP-1 therapy. Divestiture of the FC2 business and a public offering strengthened the financial position, supporting the upcoming PLATEAU trial targeting older, high-BMI patients.
Options Volatility and Implied Earnings Moves Today, December 17, 2025
Today, several major companies are expected to report earnings: ABM Industries (ABM), Enerpac Tool Group (EPAC), Veru (VERU), General Mills (GIS), MillerKnoll (MLKN), Jabil (JBL), Micron (MU), The Tor...
Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress
MIAMI, FL, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a...
Veru to Report Fiscal Year 2025 Financial Results on December 17th
MIAMI, FL, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a...
Veru to Present Two Abstracts at ObesityWeek 2025
MIAMI, FL, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a...
Veru prices 1.4M shares at $3.00 in underwritten public offering
Veru (VERU) announced the pricing of an underwritten public offering of 1,400,000 shares of its common stock, pre-funded warrants to purchase up to 7,000,000 shares of its common stock, and…
Veru announces pricing of $25M public offering
Veru (VERU) Inc. announced the pricing of an underwritten public offering of (i) 1,400,000 shares of its common stock, (ii) pre-funded warrants to purchase up to 7,000,000 shares of its…
Veru announces offering of common stock and warrants, no amount given
Veru (VERU) announced that it has commenced an underwritten public offering of shares of its common stock and accompanying Series A warrants and Series B warrants to purchase shares of…
Veru Announces Proposed Public Offering
MIAMI, FL, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a...
Veru announces FDA meeting providing regulatory clarity for Enobosarm
Veru (VERU) announced a successful meeting with FDA providing regulatory clarity for enobosarm, a selective androgen receptor modulator, as a muscle preservation drug product candidate in combination ...
Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity
MIAMI, FL, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic ...
Veru Inc. Earnings Call Transcript: Q3 2025
Phase II-B data showed enobosarm + semaglutide preserved lean mass and enhanced fat loss in older adults with obesity, with a strong safety profile. Financials reflect a narrowed focus on drug development, reduced losses, and the need for additional capital to fund Phase III trials.
Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress
--Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal side...